Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Is the ‘Holy Grail of batteries’ finally ready to bless us with its presence?

April 11, 2026

Cookiy Introduces a User Research Suite That Enables Any AI to Talk to Real People

April 11, 2026

Changing Life & Destiny Conference to Honor Dylan Gemelli with the CLD 2026 Wellness Educator Award

April 11, 2026

Umbrella Lab Announces RUO Documentation And Traceability Update For MSCs Exosomes

April 11, 2026

Ontario failed to collect nearly $10M owed by alleged animal abusers: documents

April 11, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Bronchiectasis Presents a $731.5 Million Market Opportunity: Epidemiology Forecast, Current Trends, Drug Sales, Pipeline Analysis, Unmet Needs and Key Players
Press Release

Bronchiectasis Presents a $731.5 Million Market Opportunity: Epidemiology Forecast, Current Trends, Drug Sales, Pipeline Analysis, Unmet Needs and Key Players

By News RoomJune 13, 20245 Mins Read
Bronchiectasis Presents a 1.5 Million Market Opportunity: Epidemiology Forecast, Current Trends, Drug Sales, Pipeline Analysis, Unmet Needs and Key Players
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, June 13, 2024 (GLOBE NEWSWIRE) — The “Bronchiectasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034” report has been added to ResearchAndMarkets.com’s offering.

The 7 major bronchiectasis markets reached a value of US$ 438.5 million in 2023. Looking forward, the 7MM are forecast to reach US$ 731.5 million by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2023-2034.

This report provides an exhaustive analysis of the bronchiectasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc.

The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bronchiectasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report.

Time Period of the Study:

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

The rising cases of repeated or severe respiratory infections, such as pneumonia, whooping cough, tuberculosis, etc., which cause inflammation and damage to the airway walls, are primarily driving the bronchiectasis market. In addition to this, the increasing prevalence of certain autoimmune conditions like rheumatoid arthritis, cystic fibrosis, immunodeficiency disorders, etc., that increase the risk of bronchiectasis, is also creating a positive outlook for the market. Moreover, the widespread adoption of numerous mucolytic medications, such as mannitol and hypertonic saline, since they can help in thinning the mucus, thereby rendering it easier to clear from the airways, is further augmenting the market growth.

Additionally, several key players are making extensive investments in R&D activities to investigate the potential of various biologics, including monoclonal antibodies, in reducing airway inflammation and preventing exacerbations. This, in turn, is also acting as another significant growth-inducing factor. Furthermore, the escalating demand for oscillatory positive expiratory pressure devices (OPEP), which are handheld devices that help to create vibrations in the airways during exhalation and facilitate mucus clearance, is expected to drive the bronchiectasis market in the coming years.

Countries Covered:

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country:

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the bronchiectasis market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the bronchiectasis market

This report also provides a detailed analysis of the current bronchiectasis marketed drugs and late-stage pipeline drugs:

  • Drug overview
  • Mechanism of action
  • Regulatory status
  • Clinical trial results
  • Drug uptake and market performance

Key Questions Answered in this Report:

  • Market Insights:
    • How has the bronchiectasis market performed so far and how will it perform in the coming years?
    • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
    • What was the country-wise size of the bronchiectasis market across the seven major markets in 2023 and what will it look like in 2034?
    • What is the growth rate of the bronchiectasis market across the seven major markets and what will be the expected growth over the next ten years?
    • What are the key unmet needs in the market?
  • Epidemiology Insights:
    • What is the number of prevalent cases (2018-2034) of bronchiectasis across the seven major markets?
    • What is the number of prevalent cases (2018-2034) of bronchiectasis by age across the seven major markets?
    • What is the number of prevalent cases (2018-2034) of bronchiectasis by gender across the seven major markets?
    • How many patients are diagnosed (2018-2034) with bronchiectasis across the seven major markets?
    • What is the size of the bronchiectasis patient pool (2018-2023) across the seven major markets?
    • What would be the forecasted patient pool (2024-2034) across the seven major markets?
    • What are the key factors driving the epidemiological trend of bronchiectasis?
    • What will be the growth rate of patients across the seven major markets?
  • Bronchiectasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
    • What are the current marketed drugs and what are their market performance?
    • What are the key pipeline drugs and how are they expected to perform in the coming years?
    • How safe are the current marketed drugs and what are their efficacies?
    • How safe are the late-stage pipeline drugs and what are their efficacies?
    • What are the current treatment guidelines for bronchiectasis drugs across the seven major markets?
    • Who are the key companies in the market and what are their market shares?
    • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bronchiectasis market?
    • What are the key regulatory events related to the bronchiectasis market?
    • What is the structure of clinical trial landscape by status related to the bronchiectasis market?
    • What is the structure of clinical trial landscape by phase related to the bronchiectasis market?
    • What is the structure of clinical trial landscape by route of administration related to the bronchiectasis market?

Key Attributes

Report Attribute Details
No. of Pages 138
Forecast Period 2023-2034
Estimated Market Value (USD) in 2023 $438.5 Million
Forecasted Market Value (USD) by 2034 $731.5 Million
Compound Annual Growth Rate 4.8%
Regions Covered Global

For more information about this report visit https://www.researchandmarkets.com/r/k39i6d

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Cookiy Introduces a User Research Suite That Enables Any AI to Talk to Real People

Changing Life & Destiny Conference to Honor Dylan Gemelli with the CLD 2026 Wellness Educator Award

Umbrella Lab Announces RUO Documentation And Traceability Update For MSCs Exosomes

Crypto News: AlphaPepe Announces $800k Raised While Bitcoin Price Prediction Targets $80K Breakout After Global Ceasefire

4th EXEED Global Dealer Annual Conference Gathers Global Partners; RX FL, EX8, EX6 & ES GT Interior to Premiere at Auto China

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date March 31, 2026

Dakila launches Manifesto Video and reveals Safari Brasil to the world as a new destination in the living Amazon

Toll Brothers Announces Model Grand Opening at Sereno Canyon – Enclave Collection in Scottsdale, Arizona

MOVA AtomForm Unveils 12-Nozzle Multi-Color 3D Printing System at RAPID + TCT 2026

Editors Picks

Cookiy Introduces a User Research Suite That Enables Any AI to Talk to Real People

April 11, 2026

Changing Life & Destiny Conference to Honor Dylan Gemelli with the CLD 2026 Wellness Educator Award

April 11, 2026

Umbrella Lab Announces RUO Documentation And Traceability Update For MSCs Exosomes

April 11, 2026

Ontario failed to collect nearly $10M owed by alleged animal abusers: documents

April 11, 2026

Latest News

Technical investigations underway on extending Calgary’s Blue Line LRT in northeast

April 10, 2026

‘Nobody gets free pickles on BC Ferries’: Family’s White Spot experience goes viral

April 10, 2026

Crypto News: AlphaPepe Announces $800k Raised While Bitcoin Price Prediction Targets $80K Breakout After Global Ceasefire

April 10, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version